No takes yet. Share an insight, caveat, or question.
Population pharmacokinetic study reveals that lower methotrexate levels worsen outcomes in intermediate- and high-risk paediatric leukaemia, indicating a need for individualized dose adjustments.
Chen et al. (2024) studied this question.